BIIB
reuters.dev
http://www.google.com/url?source=finance&q=http%3A%2F%2Fwww.reuters.com%2Ffinance%2Fstocks%2FBIIB.O%2Fkey-developments%2Farticle%2F2489527&ei=knKaUri3H4SQ0QGK1wE&usg=AFQjCNEWqrytLtUAJXuU5esB84SQ3bl6Nw
Samsung Biologics And Biogen Idec Inc Announce Formation Of Biosimilars Joint Venture Samsung Bioepis
Monday, 27 Feb 2012 10:00pm EST
Samsung Biologics and Biogen Idec Inc. announced that the companies have established their joint venture, Samsung Bioepis Co., Ltd., to develop, manufacture and market biosimilars in keeping with their agreement announced in December. Christopher Hansung Ko, previously Senior Vice President of Samsung Strategic Business Development, has been named the Chief Executive Officer of Samsung Bioepis. The joint venture’s Board of Directors will consist of five directors and one auditor. The strategic collaboration between Samsung Biologics and Biogen Idec will enable Samsung Bioepis to build the capabilities needed to develop high-quality biosimilars. Construction of Samsung Bioepis’ research and development center, located at Samsung Biologics’ site in Song-do Incheon, Korea, has started and will be completed by the end of the year. 
